

8<sup>TH</sup> EUROPEAN  
IMMUNOLOGY CONFERENCE

June 29-July 01, 2017 Madrid, Spain

**The fabulous history of eclampsia: An update in 2017****Pierre-Yves Robillard**

Centre Hospitalier Universitaire Sud Réunion, France

Eclampsia (together with epilepsy) being the first disease ever written down since the beginning of writings in mankind 5000 years ago, we will make a brief presentation of the different major steps in comprehension of Pre-eclampsia. 1) 1840. Rayer, description of proteinuria in eclampsia, 2) 1897 Vaquez, discovery of gestational hypertension (1 year after the invention of the inflatable arm band in 1896 by a young 31 year-old Italian physician Riva-Rocci) in eclamptic women, 3) In the 1970's, description of the "double" trophoblastic invasion existing only in humans (Brosens & Pijnenborg), 4) between the 1970's and the 1990's, description of preeclampsia being a couple disease. The "paternity problem" (and therefore irruption of immunology), 5) at the end of the 1980's, a major step forward: Preeclampsia being a global endothelial cell disease (glomeruloendotheliosis, hepatic or cerebral vasculitis, HELLP, eclampsia), inflammation (J.Roberts. C Redman, R Taylor), 6) End of the 1990's: Consensus for a distinction between early onset preeclampsia EOP and late onset LOP (34 weeks gestation), EOP being rather a problem of implantation of the trophoblast (and the placenta), LOP being rather a pre-existing maternal problem (obesity, diabetes, coagulopathies etc...). LOP is predominant everywhere on this planet, but enormously predominant in developed countries (those who publish and have the means to do research): 90% of cases. This feature is very different in countries where women have their first child very young (88% of world births), where the fatal EOP (early onset) occurs in more than 30% of cases. 7) and finally, we will approach the current stage in 2017: What is the common factor which could explain the maternal global endotheliosis in EOP and LOP?. Presentation of the inositol phosphor glycans P type.

**Biography**

Pierre-Yves Robillard, neonatologist and epidemiologist. Neonatal Department Centre Hospitalier Universitaire Sud Réunion, Centre d'Etudes Périnatales Océan-Indien (Reunion island, Indian Ocean). Medical studies University of Bordeaux, fellowship in University Hospital Pointe-à-Pitre, Guadeloupe (French West Indies). Post-Doctoral fellowship in perinatal Epidemiology at the Medical University of South-Carolina, Charleston, SC, USA (1991-1992), International EIS course CDC Atlanta, GA, USA (1992). All his career in French overseas territories

- 16 years in Guadeloupe (French West Indies)

- 3 years in Tahiti (French Polynesia)

- 18 years in Réunion island (Indian Ocean)

Chief of the PICU-NICU in the Centre Hospitalier Universitaire Sud Réunion (2002-2015).

Co-Director of the Centre d'Etudes Périnatales Océan-Indien.

Organization since 1998 of the International Workshops on Reproductive Immunology, immunological Tolerance and Immunology of Preeclampsia. (10<sup>th</sup> Edition in 2016).

robillard.reunion@wanadoo.fr

**Notes:**